Deal or No Deal with NYT’s Tom Friedman; Vaccines, Strains, & Safety with Dr. Atul Gawande

After last minute input from President Trump, the $900B relief bill passed by Congress may be back to the negotiating table. The New York Times Columnist Tom Friedman shares why the situation is “suboptimal” across the board, and he discusses what’s next for lawmakers and Americans awaiting aid. Surgeon at Brigham and Women’s Hospital and staff writer for The New Yorker Dr. Atul Gawande discusses coronavirus risks ahead of the holidays and the likelihood of a Covid mutation spreading worldwide. Plus, the last days of the holiday shopping season are upon us, and Fanatics Executive Chairman Michael Rubin says the pandemic has accelerated demand for e-commerce options. Head of the sports swag e-retailer quizzes the Squawk team on the season’s most popular merchandise, and considers the tough road ahead for logistics companies.